Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study
10.3760/cma.j.cn501113-20231124-00223
- VernacularTitle:经皮微波消融治疗肝细胞癌的生存疗效:一项15年的真实世界研究
- Author:
Yanchun LUO
1
;
Manlin LANG
;
Wenjia CAI
;
Zhiyu HAN
;
Fangyi LIU
;
Zhigang CHENG
;
Xiaoling YU
;
Jianping DOU
;
Xin LI
;
Shuilian TAN
;
Xuejuan DONG
;
Ping LIANG
;
Jie YU
Author Information
1. 中国人民解放军总医院第五医学中心超声诊断科,北京 100166
- Keywords:
Hepatocellular carcinoma;
Treatment;
Microwave ablation;
Survival rate;
Real-world experience
- From:
Chinese Journal of Hepatology
2024;32(4):332-339
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the long-term efficacy of percutaneous microwave ablation (MWA) therapy for hepatocellular carcinoma.Methods:2054 cases with Barcelona Clinic Liver Cancer (BCLC) stage 0~B at the Fifth Medical Center of the Chinese People's Liberation Army General Hospital from January 2006 to September 2020 were retrospectively collected. All patients were followed up for at least 2 years. The primary endpoint of overall survival and secondary endpoints (tumor-related survival, disease-free survival, and postoperative complications) of patients treated with ultrasound-guided percutaneous MWA were analyzed. Kaplan-Meier method was used for stratified survival rate analysis. Fine-and-Gray competing risk model was used to analyze overall survival.Results:A total of 5 503 HCC nodules [mean tumor diameter (2.6±1.6) cm] underwent 3 908 MWAs between January 2006 and September 2020, with a median follow-up time of 45.6 (24.0 -79.2) months.The technical effectiveness rate of 5 375 tumor nodules was 97.5%. The overall survival rates at 5, 10, and 15-years were 61.6%, 38.8%, and 27.0%, respectively. The tumor-specific survival rates were 67.1%, 47.2%, and 37.7%, respectively. The free tumor survival rates were 25.8%, 15.7%, and 9.9%, respectively. The incidence rate of severe complications was 2.8% (108/3 908). Further analysis showed that the technical effectiveness and survival rate over the passing three time periods from January 2006-2010, 2011-2015, and 2016-September 2020 were significantly increased, with P ?0.001, especially for liver cancer 3.1~5.0 cm ( P ?0.001). Conclusion:Microwave ablation therapy is a safe and effective method for BCLC stage 0-B, with significantly enhanced technical efficacy and survival rate over time.